Zydus Lifesciences
Indian generics and pharma major, formerly Cadila Healthcare, ~$2.4B revenue.
On the record
Checkpoint: Mirabegron settlement exclusivity expires, opening the field to more generic entrants
The call
Zydus runs a profitable, diversified generics business, but its growth still leans hard on two aging exclusivities and a US market facing tariff uncertainty.
Zydus Lifesciences makes and sells generic drugs and branded medicines from India, with over 400 products approved by U.S. regulators. The company is profitable and has real advantages: it owns factories that meet global safety standards and sells widely across India. The main problem is that nearly half its revenue comes from just two drugs (Revlimid and Mirabegron), which face price pressure and competition from other drugmakers, and about 40 percent of sales come from the U.S., which could shrink if tariffs go up. The company recently bought three smaller competitors to diversify, but whether those deals work out and whether it can launch new profitable products before its top two drugs lose sales will decide if this company stays healthy or runs into trouble.
Why
01
AI pressure: AI drug discovery labs (Recursion, Insilico, Isomorphic Labs). These labs target novel molecule discovery, not generics manufacturing, so Zydus's core ANDA business stays largely untouched for now. Could AI do the core job? Unlikely.
02
Bigger players: Teva, Sun Pharma, Dr Reddy's and other generic makers chasing the same off-patent drugs. As Revlimid and Mirabegron exclusivity windows close, more generic rivals pile into the same molecules Zydus depends on for half its revenue. Could a giant copy it? Probably.
03
What protects it. 424 USFDA plant approvals plus deep India distribution give Zydus manufacturing scale and regulatory trust that's slow to replicate.
What would change this call
Zydus's Palbociclib (generic Ibrance) launch date confirmed for FY28 or slips further. Shows whether diversification away from Revlimid/Mirabegron concentration is on track.
US tariff rate on Indian pharma imports set at expiry of 2028 grace period. Shows how much of Zydus's ~40-44% US revenue exposure turns into real cost pressure.
Mirabegron exclusivity settlement expires September 2027 and generic competitors enter. Shows how fast a core revenue product eroded once protection lapsed.
US tariff rate on Indian pharma imports set at expiry of 2028 grace period. Shows how much of Zydus's ~40-44% US revenue exposure turns into real cost pressure.
Mirabegron exclusivity settlement expires September 2027 and generic competitors enter. Shows how fast a core revenue product eroded once protection lapsed.
Key numbers
- Q4 FY26 revenue ₹75,870mn, up 16.2% YoY
- Revlimid and Mirabegron are ~49% of revenue
- US market is 40-44% of total revenue
Named risks
- US tariff plan proposes 100% then 200% duties on generics starting 2028 vs ~40-44% US revenue exposure.
- Revlimid and Mirabegron together made up about 49% of revenue as of August 2025, a concentration risk.
- Three acquisitions (Amplitude, Zylidac, Assertio) closed within about 12 months, raising integration execution risk.
- Ongoing Mirabegron royalty and $120mn settlement obligation to Astellas through September 2027.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Sun Pharma | contesting | Described as India branded-formulations scale leader in July 2026 tariff coverage |
| Aurobindo Pharma | contesting | Carries higher US revenue exposure (~46-49%) than Zydus amid July 2026 tariff threat |
| Dr. Reddy's Laboratories | contesting | Simultaneously launched generic semaglutide in India, March 21, 2026 |
| Novo Nordisk | gaining on | Zydus launched generic semaglutide brands after India patent expiry, March 2026 |
| Astellas | contesting | Zydus paid $120mn plus royalties through Sep 2027 to keep selling mirabegron, Feb 2026 |
Questions people ask
- Is Zydus Lifesciences profitable?
- Yes. Zydus reported FY25 net income of about ₹47.45 billion on revenue of ₹232.4 billion (year ended March 31, 2025). Q4 FY26 adjusted net profit was ₹15,929 million on revenue of ₹75,870 million, up 16.2% year over year, per its May 19, 2026 press release.
- Who owns Zydus Lifesciences?
- Zydus is publicly traded on the BSE and NSE, but the founding Patel family remains the controlling shareholder with roughly 75% promoter stake as of the March 2026 shareholding pattern. It is not a subsidiary of any other company.
- Could AI replace Zydus Lifesciences?
- Unlikely in its core business. Zydus's revenue is dominated by generics manufacturing, ANDA filings, and India distribution, backed by 424 cumulative USFDA approvals as of April 2025, GMP-scale plants, and physician networks that AI drug-discovery tools do not substitute for.
- Who is Zydus Lifesciences' biggest competitor?
- Zydus competes with fellow Indian pharma majors Sun Pharma, Cipla, Dr. Reddy's, Lupin, and Aurobindo Pharma, all exposed to the same US generics and tariff pressures reported in July 2026 coverage of Trump's proposed generic-drug tariff plan.
- Is Zydus Lifesciences exposed to US tariffs?
- Yes. Zydus derives roughly 40-44% of revenue from the US market. On July 21-22, 2026, President Trump proposed phased generic-drug tariffs (0% for two years, then 100% and 200%), and Zydus shares fell about 2.7% on the news.
- What happened with Zydus's Mirabegron patent dispute?
- On February 12, 2026, Zydus agreed to pay Astellas $120 million plus per-unit licensing fees through September 2027 to settle Myrbetriq/mirabegron patent litigation, securing continued US marketing rights for the drug.
Timeline
- 2026-07-22Trump proposes phased generic-drug tariffs; Zydus shares fall about 2.7%
- 2026-06-16Zydus completes $23.50/share tender offer merger with Assertio Holdings
- 2026-05-28Zydus raises buyback price to ₹1,260/share, repurchases 87.3 lakh shares
- 2026-05-19Q4 and FY26 results released; FY27 guidance of high-teens growth issued
- 2026-03-21Zydus launches generic semaglutide (Semaglyn, Mashema, Alterme) in India
- 2026-02-12Zydus agrees to pay Astellas $120mn to settle Mirabegron patent litigation
- 2026-01-15Zydus completes Agenus biologics facility acquisition, launches Zylidac Bio LLC
- 2025-10-26Zydus completes squeeze-out to 100% ownership of Amplitude Surgical
- 2025-07-29Zydus completes €256mn acquisition of 85.6% stake in Amplitude Surgical
- 2025-04-11Zydus reaches 424 cumulative USFDA approvals with Jaythari (deflazacort) nod
Revision history
25 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Zydus Lifesciences Limited (infobox)
- Zydus Q1 FY26 Financial Performance (2025-08-12)
- Zydus Q2 & H1 FY26 Financial Performance (2025-11-06)
- Zydus Q4 & FY26 Press Release (2026-05-19)
- Zydus Lifesciences Q1 Results 2026 (2026-07-16)
- Systematix Result Update (2025-08-13)
- Zydus Q4 & FY26 Investor Presentation (2026-05-19)
- ZYDUSLIFE Earnings Call Transcripts
- NDTV Profit tariff impact story (2026-07-21)
- Zydus Lifesciences Reduces Buyback Size (2026-05-27)
- Zydus Lifesciences raises share buyback price, cuts share count (2026-05-28)
- gurufocus.com (2026-07-25)